Skip to main content
SpringerLink
Log in

Cardiotoxicity

  • Chapter
  • First Online:
Book cover Side Effects of Medical Cancer Therapy

Abstract

While outcomes in cancer patients have dramatically improved with the development of novel cancer chemotherapies and combination treatment, this is nonetheless associated with emerging concerns over drug-induced cardiotoxicity. Moreover, the recent incorporation of targeted therapies into therapeutic regimens has widened the cardiotoxic spectrum. Awareness of anticancer drug-induced cardiotoxicity is essential for adequate patient monitoring and early cardiotoxicity detection and treatment. This rising concern is also reflected in drug development, as efforts have been made to improve the characterization of potential cardiotoxicity of new compounds during the early phases of development and to design safer drugs. This chapter summarizes the major cardiotoxic effects and pathophysiology of a large number of antineoplastic treatments currently in use. Existing recommendations for early treatment and future development are also described.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–82.

    Article  PubMed  CAS  Google Scholar 

  2. Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the childhood cancer survivor study. J Clin Oncol. 2009;27(14):2328–38.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Armenian SH, Bhatia S. Cardiovascular disease after hematopoietic cell transplantation – lessons learned. Haematologica. 2008;93(8):1132–6.

    Article  PubMed  CAS  Google Scholar 

  4. Tukenova M, Guibout C, Oberlin O, Doyon F, Mousannif A, Haddy N, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010;28(8):1308–15.

    Article  PubMed  Google Scholar 

  5. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol. 2010;7(10):564–75.

    Article  PubMed  Google Scholar 

  6. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14–25.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23(13):2900–2.

    Article  PubMed  CAS  Google Scholar 

  8. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2006;5(6):791–809.

    Article  PubMed  CAS  Google Scholar 

  9. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47.

    Article  PubMed  CAS  Google Scholar 

  10. Brana I, Tabernero J. Cardiotoxicity. Ann Oncol. 2010;21(Suppl 7):vii173–vii9.

    PubMed  Google Scholar 

  11. Steinberg JS, Cohen AJ, Wasserman AG, Cohen P, Ross AM. Acute arrhythmogenicity of doxorubicin administration. Cancer. 1987;60(6):1213–8.

    Article  PubMed  CAS  Google Scholar 

  12. Harrison DT, Sanders LA. Pericarditis in a case of early daunorubicin cardiomyopathy. Ann Intern Med. 1976;85(3):339–41.

    Article  PubMed  CAS  Google Scholar 

  13. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(12):2629–36.

    Article  PubMed  CAS  Google Scholar 

  14. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337. Epub 2010/07/01.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Von Hoff DD, Layard MW, Basa P. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710–7.

    Article  Google Scholar 

  16. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Assoc. 1991;266(12):1672–7.

    Article  CAS  Google Scholar 

  17. Hershman DL, McBride RB, Eisenberger A, Wei YT, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26(19):3159–65.

    Article  PubMed  CAS  Google Scholar 

  18. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–79.

    Article  PubMed  CAS  Google Scholar 

  19. Wang X, Liu W, Sun C-L, Armenian SH, Hakonarson H, Hageman L, et al. Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children’s oncology group. J Clin Oncol. 2014;32(7):647–53.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Lyu YL, Kerrigan JE, Lin C-P, Azarova AM, Tsai Y-C, Ban Y, et al. Topoisomerase IIβ–mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67(18):8839–46.

    Article  PubMed  CAS  Google Scholar 

  21. Billingham ME, Bristow MR, Glatstein E, Mason JW, Masek MA, Daniels JR. Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol. 1977;1(1):17–23. Epub 1977/03/01.

    Article  PubMed  CAS  Google Scholar 

  22. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978;62(6):865–72. Epub 1978/06/01.

    PubMed  CAS  Google Scholar 

  23. Mackay B, Ewer MS, Carrasco CH, Benjamin RS. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol. 1994;18(1–2):203–11. Epub 1994/01/01.

    Article  PubMed  CAS  Google Scholar 

  24. van Dalen EC, van der Pal Helena JH, Caron Huib N, Kremer Leontien CM. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2009;4:CD005008. Available from: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005008/frame.html

    Google Scholar 

  25. Bonneterre J, Roché H, Kerbrat P, Fumoleau P, Goudier MJ, Fargeot P, et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French Adjuvant Study Group. J Clin Oncol. 2004;22(15):3070–9.

    Article  PubMed  CAS  Google Scholar 

  26. Jain KK, Casper ES, Geller NL. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol. 1985;3(6):818–26.

    Article  PubMed  CAS  Google Scholar 

  27. Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst. 2008;100(15):1058–67.

    Article  PubMed  CAS  Google Scholar 

  28. Bedano PM, Brames MJ, Williams SD, Juliar BE, Einhorn LH. Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors. J Clin Oncol. 2006;24(34):5403–7.

    Article  PubMed  CAS  Google Scholar 

  29. Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, et al. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol. 1999;17(5):1425–34.

    Article  PubMed  CAS  Google Scholar 

  30. van Dalen EC, Michiels Erna MC, Caron Huib N, Kremer Leontien CM. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010;5:CD005006. Available from: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005006/frame.html

    Google Scholar 

  31. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27(1):127–45.

    Article  PubMed  CAS  Google Scholar 

  32. Posner LE, Dukart G, Goldberg J. Mitoxantrone: an overview of safety and toxicity. Investig New Drugs. 1985;3(2):123–32.

    Article  CAS  Google Scholar 

  33. Dow E, Schulman H, Agura E. Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant. 1993;12(2):169–72.

    PubMed  CAS  Google Scholar 

  34. Katayama M, Imai Y, Hashimoto H, Kurata M, Nagai K, Tamita K, et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol. 2009;54(2):330–4.

    Article  PubMed  Google Scholar 

  35. Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol. 2010;21(11):2153–60.

    Article  PubMed  CAS  Google Scholar 

  36. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7(5):332–44.

    Article  PubMed  CAS  Google Scholar 

  37. Grazette LP, Boecker W, Matsui T, Semigran M, Force TL, Hajjar RJ, et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol. 2004;44(11):2231–8.

    Article  PubMed  CAS  Google Scholar 

  38. de Korte MA, de Vries EGE, Lub-de Hooge MN, Jager PL, Gietema JA, van der Graaf WTA, et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer. 2007;43(14):2046–51.

    Article  PubMed  CAS  Google Scholar 

  39. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–21.

    Article  PubMed  CAS  Google Scholar 

  40. Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2–overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23(31):7811–9.

    Article  PubMed  CAS  Google Scholar 

  41. Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol. 2011;23(4):897–902.

    Article  PubMed  Google Scholar 

  42. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92. Epub 2001/03/15.

    Article  PubMed  CAS  Google Scholar 

  43. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.

    Article  PubMed  CAS  Google Scholar 

  44. Romond EH, Jeong J-H, Rastogi P, Swain SM, Jr CEG, Ewer MS, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol. 2012;30(31):3792–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–83.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014;3(1):e000472.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83(6):679–86.

    Article  PubMed  Google Scholar 

  48. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. Food and Drug Administration. Ado-Trastuzumab emtansine: highlights of prescribing information. 2016 [12 Dec 2016]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125427s096lbl.pdf.

  50. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, et al. Phase II Trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28(7):1138–44.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Swain SM, Ewer MS, Cortés J, Amadori D, Miles D, Knott A, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist. 2013;18(3):257–64.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Food and Drug Administration. Pertuzumab: highlights of prescribing information. 2016 [12 Dec 2016]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125409s109lbl.pdf.

  53. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36(5):295–316.

    Article  PubMed  CAS  Google Scholar 

  54. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110(4):1233–7.

    Article  PubMed  CAS  Google Scholar 

  56. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908–16.

    Article  PubMed  CAS  Google Scholar 

  57. Food & Drug Administration US. VELCADE® prescribing information. 2011 [cited 2011 14 Nov]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021602s029s030lbl.pdf.

  58. Fu HY, Minamino T, Tsukamoto O, Sawada T, Asai M, Kato H, et al. Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition. Cardiovasc Res. 2008;79(4):600–10.

    Article  PubMed  CAS  Google Scholar 

  59. Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol. 2016;34(10):1122–30.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma. 2016;57(6):1300–10.

    Article  PubMed  CAS  Google Scholar 

  61. De Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol. 1992;10(11):1795–801.

    Article  PubMed  Google Scholar 

  62. Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil [2]. Ann Oncol. 2002;13(3):484–5.

    Article  PubMed  Google Scholar 

  63. Rezkalla S, Kloner RA, Ensley J, Al-Sarraf M, Revels S, Olivenstein A, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol. 1989;7(4):509–14.

    Article  PubMed  CAS  Google Scholar 

  64. Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134(1):75–82.

    Article  PubMed  CAS  Google Scholar 

  65. Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009;8(2):191–202.

    Article  PubMed  CAS  Google Scholar 

  66. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther. 2006;6(9):1249–69.

    Article  PubMed  CAS  Google Scholar 

  67. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol. 2003;21(18):3542.

    Article  PubMed  Google Scholar 

  68. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232–9.

    Article  PubMed  Google Scholar 

  69. Sugrue M, Yi J, Purdie D, Dong W, Grothey A, Kozloff M. Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV): results from the BRiTE registry. Proc Am Soc Clin Oncol. 2007;25:4136.

    Google Scholar 

  70. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204–12.

    Article  PubMed  Google Scholar 

  71. Food and Drug Administration. Axitinib: highlights of prescribing information. 2014 [11 Dec 2016]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202324s002lbl.pdf.

  72. Food and Drug Administration. Pazopanib: highlights of prescribing information. 2016 [11 Dec 2016]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022465s023lbl.pdf.

  73. Food and Drug Administration. Nintedanib: highlights of prescribing information. 2014 [11 Dec 2016]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202324s002lbl.pdf.

  74. Food and Drug Administration. Regorafenib: highlights of prescribing information. 2016 [11 Dec 2016]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203085s006lbl.pdf.

  75. Food and Drug Administration. Cabozantinib: highlights of prescribing information. 2016 [11 Dec 2016]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203756s002lbl.pdf.

  76. Food and Drug Administration. Lenvatinib: highlights of prescribing information. 2016 [11 Dic 2016]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206947s003lbl.pdf.

  77. Food and Drug Administration. Ponatinib: highlights of prescription information. 2016 [11 Dec 2016]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203469s022lbl.pdf.

  78. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol. 2007;25(22):3362–71.

    Article  PubMed  CAS  Google Scholar 

  79. Ederhy S, Cohen A, Dufaitre G, Izzedine H, Massard C, Meuleman C, et al. QT interval prolongation among patients treated with angiogenesis inhibitors. Target Oncol. 2009;4(2):89–97.

    Article  PubMed  Google Scholar 

  80. Morgan C, Tillett T, Braybrooke J, Ajithkumar T. Management of uncommon chemotherapy-induced emergencies. Lancet Oncol. 2011;12(8):806–14.

    Article  PubMed  Google Scholar 

  81. Al-Khatib SM, Allen LaPointe NM, Kramer JM, Califf RM. What Clinicians Should Know about the QT Interval. J Am Med Assoc. 2003;289(16):2120–7.

    Article  Google Scholar 

  82. Viskin S, Rosovski U, Sands AJ, Chen E, Kistler PM, Kalman JM, et al. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm. 2005;2(6):569–74.

    Article  PubMed  Google Scholar 

  83. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80(5):795–803.

    Article  PubMed  CAS  Google Scholar 

  84. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A. 2000;97(22):12329–33.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Raschi E, Vasina V, Poluzzi E, De Ponti F. The hERG K+ channel: target and antitarget strategies in drug development. Pharmacol Res. 2008;57(3):181–95.

    Article  PubMed  CAS  Google Scholar 

  86. Varterasian M, Fingert H, Agin M, Meyer M, Cooney M, Radivoyevitch T, et al. Consideration of QT/QTc interval data in a phase I study in patients with advanced cancer (multiple letters) [1]. Clin Cancer Res. 2004;10(17):5967–9.

    Article  PubMed  Google Scholar 

  87. Davey P. How to correct the QT interval for the effects of heart rate in clinical studies. J Pharmacol Toxicol Methods. 2002;48(1):3–9.

    Article  PubMed  CAS  Google Scholar 

  88. Bates SE, Rosing DR, Fojo T, Piekarz RL. Challenges of evaluating the cardiac effects of anticancer agents. Clin Cancer Res. 2006;12(13):3871–4.

    Article  PubMed  CAS  Google Scholar 

  89. Yarnoz MJ, Curtis AB. More reasons why men and women are not the same (gender differences in electrophysiology and arrhythmias). Am J Cardiol. 2008;101(9):1291–6.

    Article  PubMed  Google Scholar 

  90. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine. 2003;82(4):282–90.

    PubMed  Google Scholar 

  91. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. J Am Med Assoc. 2002;287(17):2215–20.

    Article  Google Scholar 

  92. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: the clinical evaluation of QT/QTc interval prolongation and pro-arrhythmic potential for non-antiarrhythmic drugs E14. 2005 [cited 2011 17 Nov]; Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/Step4/E14_Guideline.pdf.

  93. Sarapa N, Britto MR. Challenges of characterizing proarrhythmic risk due to QTc prolongaton induced by nonadjuvant anticancer agents. Expert Opin Drug Saf. 2008;7(3):305–18.

    Article  PubMed  CAS  Google Scholar 

  94. Food & Drug Administration US. TASIGNA® label information. 2011 [cited 2011 14 Nov]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022068s007lbl.pdf.

  95. Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12(12):3762–73.

    Article  PubMed  CAS  Google Scholar 

  96. Becker TK, Yeung SCJ. Drug-induced QT interval prolongation in cancer patients. Oncol Rev. 2010;4(4):223–32.

    Article  Google Scholar 

  97. Nousiainen T, Vanninen E, Rantala A, Jantunen E, Hartikainen J. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin’s lymphoma. J Intern Med. 1999;245(4):359–64. Epub 1999/06/05.

    Article  PubMed  CAS  Google Scholar 

  98. Kuittinen T, Jantunen E, Vanninen E, Mussalo H, Nousiainen T, Hartikainen J. Late potentials and QT dispersion after high-dose chemotherapy in patients with non-Hodgkin lymphoma. Clin Physiol Funct Imaging. 2010;30(3):175–80. Epub 2010/02/06.

    Article  PubMed  CAS  Google Scholar 

  99. Pudil R, Horacek J, Vojacek J, Jakl M. Anthracycline therapy induces very early increase in QT dispersion and QTc prolongation. Circulation. 2010;122(2):e385.

    Google Scholar 

  100. Owczuk R, Wujtewicz MA, Sawicka W, Wujtewicz M, Swierblewski M. Is prolongation of the QTc interval during isoflurane anaesthesia more prominent in women pretreated with anthracyclines for breast cancer? Br J Anaesth. 2004;92(5):658–61. Epub 2004/04/06.

    Article  PubMed  CAS  Google Scholar 

  101. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19(18):3852–60.

    Article  PubMed  CAS  Google Scholar 

  102. Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21(19):3609–15.

    Article  PubMed  CAS  Google Scholar 

  103. Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J. 2010;40(4):303–7. Epub 2010/06/10.

    Article  PubMed  CAS  Google Scholar 

  104. Wacker A, Lersch C, Scherpinski U, Reindl L, Seyfarth M. High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology. 2003;65(2):108–12. Epub 2003/08/22.

    Article  PubMed  CAS  Google Scholar 

  105. Nakamae H, Tsumura K, Hino M, Hayashi T, Tatsumi N. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. Lancet. 2000;355(9206):805–6.

    Article  PubMed  CAS  Google Scholar 

  106. Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2006;12(13):3997–4003.

    Article  PubMed  CAS  Google Scholar 

  107. Food & Drug Administration US. ISTODAX® prescribing information. 2011; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022393s006lbl.pdf.

  108. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous t-cell lymphoma. J Clin Oncol. 2007;25(21):3109–15.

    Article  PubMed  CAS  Google Scholar 

  109. Munster PN, Rubin EH, Van Belle S, Friedman E, Patterson JK, Van Dyck K, et al. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res. 2009;15(22):7077–84.

    Article  PubMed  CAS  Google Scholar 

  110. Food & Drug Administration US. ZOLINZA® prescribing information. 2011 [cited 2011 14 Nov]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf.

  111. Zhang L, Lebwohl D, Masson E, Laird G, Cooper MR, Prince HM. Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat) [1]. J Clin Oncol. 2008;26(2):332–3.

    Article  PubMed  CAS  Google Scholar 

  112. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006;12(15):4628–35.

    Article  PubMed  CAS  Google Scholar 

  113. Sharma S, Vogelzang N, Beck J, Patnaik A, Mita M, Dugan M. Phase I pharmacokinetic and pharmacodynamic study of once-weekly iv panobinostat (LBH589). Barcelona: ECCO Poster; 2007. p. 23–7.

    Google Scholar 

  114. Wells S, Robinson B, Gagel R, Dralle H, Fagin J, Santoro M, et al. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA). J Clin Oncol. 2010;28(15_suppl):5503.

    Article  Google Scholar 

  115. Food & Drug Administration US. CAPRELSA® (vandetanib) tablets. Prescription information. 2011 [cited 2011 14 Nov]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s001lbl.pdf.

  116. Food & Drug Administration US. SUTENT®. Prescription information. 2011 [cited 2011 14 Nov]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021938s13s17s18lbl.pdf.

  117. Shah RR, Morganroth J. Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on qt interval, left ventricular dysfunction and overall risk/benefit. Drug Saf. 2015;38(8):693–710.

    Article  PubMed  CAS  Google Scholar 

  118. Kloth JS, Pagani A, Verboom MC, Malovini A, Napolitano C, Kruit WH, et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer. 2015;112(6):1011–6. Epub 2015/03/06.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  119. Food & Drug Administration US. SPRYCEL® prescribing information. 2011 [cited 2011 14 Nov]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021986s009s010lbl.pdf.

  120. Abbas R, Chalon S, Leister C, El Gaaloul M, Sonnichsen D. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol. 2013;71(1):123–32. Epub 2012/10/12.

    Article  PubMed  CAS  Google Scholar 

  121. Arkenau H-T, Sachdev JC, Mita MM, Dziadziuszko R, Lin C-C, Yang JC, et al. Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer. ASCO Meeting Abstracts. 2015;33(15_suppl):8063.

    Google Scholar 

  122. Food and Drug Administration. TAGRISSO™ (osimertinib): highlights of prescribing information. 2015.

    Google Scholar 

  123. Goldman JW, Soria J-C, Wakelee HA, Camidge DR, Gadgeel SM, Yu HA, et al. Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. 2016;34(15_suppl):9045.

    Google Scholar 

  124. Spreafico A, Delord JP, De Mattos-Arruda L, Berge Y, Rodon J, Cottura E, et al. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. Br J Cancer. 2015;112(4):650–9. Epub 2015/01/28.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  125. Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M, et al. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res. 2013;19(13):3671–80.

    Article  PubMed  CAS  Google Scholar 

  126. Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, et al. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res. 2011;17(21):6831–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  127. Reddy N, Voorhees PM, Houk BE, Brega N, Hinson JM Jr, Jillela A. Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2013;13(4):385–91. Epub 2013/06/15.

    Article  PubMed  CAS  Google Scholar 

  128. Dennis A, Wang L, Wan X, Ficker E. hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans. 2007;35(5):1060–3.

    Article  PubMed  CAS  Google Scholar 

  129. Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol. 2015;33(9):1060–6. Epub 2015/01/22.

    Article  PubMed  CAS  Google Scholar 

  130. Quinn DI, Baudin E, Demeure MJ, Fassnacht M, Hammer GD, Poondru S, et al. International randomized, double-blind, placebo-controlled, phase 3 study of linsitinib (OSI-906, L) in patients (pts) with locally advanced or metastatic adrenocortical carcinoma (ACC). ASCO Meeting Abstracts. 2014;32(15_suppl):4507.

    Google Scholar 

  131. Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, Van Maanen R, Vermaat JS, et al. Phase I pharmacokinetic and pharmacodynamic studyof the oral protein kinase C β-inhibitor enzastaurin in combination with gemcitabine and cisplatinin patients with advanced cancer. Clin Cancer Res. 2007;13(15):4474–81.

    Article  PubMed  CAS  Google Scholar 

  132. Welch PA, Sinha VP, Cleverly AL, Darstein C, Flanagan SD, Musib LC. Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-β inhibitor, in healthy subjects. J Clin Pharmacol. 2007;47(9):1138–51.

    Article  PubMed  CAS  Google Scholar 

  133. Kreisl TN, Kim L, Moore K, Duic P, Kotliarova S, Walling J, et al. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res. 2009;15(10):3617–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  134. Kreisl TN, Kotliarova S, Butman JA, Albert PS, Kim L, Musib L, et al. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro-Oncology. 2010;12(2):181–9. Epub 2010/02/13.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  135. Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, et al. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol. 2008;26(7):1135–41.

    Article  PubMed  CAS  Google Scholar 

  136. Hanrahan EO, Kies MS, Glisson BS, Khuri FR, Feng L, Tran HT, et al. A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2009;32(3):274–9. Epub 2009/05/13.

    Article  PubMed  CAS  Google Scholar 

  137. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002;62(12):3408–16.

    PubMed  CAS  Google Scholar 

  138. Tabernero J, Dirix L, Schöfski P, Cervantes A, Lopez-Martin JA, Capdevila J, et al. A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin Cancer Res. 2011;17(19):6313–21.

    Article  PubMed  CAS  Google Scholar 

  139. Slovacek L, Ansorgova V, Macingova Z, Haman L, Petera J. Tamoxifen-induced QT interval prolongation. J Clin Pharm Ther. 2008;33(4):453–5.

    Article  PubMed  CAS  Google Scholar 

  140. Garnick MB, Pratt CM, Campion M, Shipley J. The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. ASCO Meeting Abstracts. 2004;22(14_suppl):4578.

    Google Scholar 

  141. Guglin M, Aljayeh M, Saiyad S, Ali R, Curtis AB. Introducing a new entity: chemotherapy-induced arrhythmia. Europace. 2009;11(12):1579–86.

    Article  PubMed  Google Scholar 

  142. Rowinsky EK, Donehower RC. Drug therapy: paclitaxel (taxol). N Engl J Med. 1995;332(15):1004–14.

    Article  PubMed  CAS  Google Scholar 

  143. Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9(9):1704–12.

    Article  PubMed  CAS  Google Scholar 

  144. Food & Drug Administration US. ABRAXANE® for injectable suspension (paclitaxel protein-bound particles for injectable suspension) labeling revision. 2009 [cited 2011 14 Nov]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021660s022lbl.pdf.

  145. Ou SH, Tong WP, Azada M, Siwak-Tapp C, Dy J, Stiber JA. Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer. 2013;119(11):1969–75. Epub 2013/03/19.

    Article  PubMed  CAS  Google Scholar 

  146. Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009;15(19):6250–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  147. JF Morere, Des Guetz G, J Mourad, BI Lévy, J Breau. Mechanism of bevacizumab-induced arterial hypertension: relation with skin capillary rarefaction in patients treated for metastatic colorectal cancer. ASCO annual meeting; 2007. Abst 35572007.

    Google Scholar 

  148. de Boer MP, van der Veldt AAM, Lankheet NA, Wijnstok NJ, van den Eertwegh AJM, Boven E, et al. Sunitinib-induced reduction in skin microvascular density is a reversible phenomenon. Ann Oncol. 2010;21(9):1923–4.

    Article  PubMed  Google Scholar 

  149. Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res. 2008;14(11):3470–6.

    Article  PubMed  CAS  Google Scholar 

  150. Steeghs N, Rabelink TJ, op ‘t Roodt J, Batman E, Cluitmans FHM, Weijl NI, et al. Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol. 2010;21(5):1100–5.

    Article  PubMed  CAS  Google Scholar 

  151. van der Veldt AAM, de Boer MP, Boven E, Eringa EC, van den Eertwegh AJM, van Hinsbergh VW, et al. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anti-Cancer Drugs. 2010;21(4):439–46. https://doi.org/10.1097/CAD.0b013e3283359c79.

    Article  PubMed  CAS  Google Scholar 

  152. Demetri GD Van Oosterom AT, Blackstein M, Garrett C, Shah M, Heinrich M, McArthur G, Judson I, Baum CM, Casali PG. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST. ASCO annual meeting 2005; abst 4000. 2005.

    Google Scholar 

  153. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. J Am Med Assoc. 2006;295(21):2516–24.

    Article  CAS  Google Scholar 

  154. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006;12(24):7271–8.

    Article  PubMed  CAS  Google Scholar 

  155. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21(1):60–5.

    Article  PubMed  CAS  Google Scholar 

  156. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.

    Article  PubMed  CAS  Google Scholar 

  157. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160(6, Part 1):2021–4.

    Article  PubMed  CAS  Google Scholar 

  158. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  159. Rajkumar SV. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc. 2005;80(12):1549–51.

    Article  PubMed  Google Scholar 

  160. Rodeghiero F, Elice F. Thalidomide and thrombosis. Pathophysiol Haemost Thromb. 2003;33(Suppl. 1):15–8.

    Article  PubMed  Google Scholar 

  161. Food & Drug Administration US. TARCEVA® prescribing information. 2010 [cited 2011 14 Nov]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf.

  162. Qi WX, Min DL, Shen Z, Sun YJ, Lin F, Tang LN, et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int J Cancer. 2013;132(12):2967–74. Epub 2012/12/12.

    Article  PubMed  CAS  Google Scholar 

  163. Sonpavde G, Je Y, Schutz F, Galsky MD, Paluri R, Rosenberg JE, et al. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2013;87(1):80–9.

    Article  PubMed  Google Scholar 

  164. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414–23.

    Article  CAS  PubMed  Google Scholar 

  165. Deitcher SR, Gomes MPV. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer. 2004;101(3):439–49.

    Article  PubMed  Google Scholar 

  166. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–57.

    Article  PubMed  Google Scholar 

  167. Al-Mubarak M, Sacher AG, Ocana A, Vera-Badillo F, Seruga B, Amir E. Fulvestrant for advanced breast cancer: a meta-analysis. Cancer Treat Rev. 2013;39(7):753–8. Epub 2013/06/15.

    Article  PubMed  CAS  Google Scholar 

  168. Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, et al. Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol. 2004;22(15):3139–48.

    Article  PubMed  Google Scholar 

  169. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. J Am Med Assoc. 1993;270(16):1949–55.

    Article  CAS  Google Scholar 

  170. Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66(4):309–25. Epub 2016/02/27.

    Article  PubMed  Google Scholar 

  171. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606.

    Article  PubMed  PubMed Central  Google Scholar 

  172. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the childhood cancer survivor study cohort. BMJ. 2010;340(7736):34.

    Google Scholar 

  173. Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines. Ann Oncol. 2010;21(Suppl. 5):v277–v82.

    Article  PubMed  Google Scholar 

  174. Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13(1):1–10.

    Article  PubMed  Google Scholar 

  175. Soto-Matos A, Szyldergemajn S, Extremera S, Miguel-Lillo B, Alfaro V, Coronado C, et al. Plitidepsin has a safe cardiac profile: a comprehensive analysis. Mar Drugs. 2011;9(6):1007–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  176. Cheng H, Force T. Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis. 2010;53(2):114–20.

    Article  PubMed  CAS  Google Scholar 

  177. Fernandez A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest. 2007;117(12):4044–54.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  178. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: the non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. S7B. 2005; Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf.

  179. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474–81.

    Article  PubMed  CAS  Google Scholar 

  180. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258–62.

    Article  PubMed  CAS  Google Scholar 

  181. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2005(1):CD003917.

    Google Scholar 

  182. Food & Drug Administration US. ZINECARD® approved labeling. 2005 [cited 2011 14 Nov]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020212s008lbl.pdf.

  183. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013;26(5):493–8. Epub 2013/04/09.

    Article  PubMed  Google Scholar 

  184. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801. Epub 2016/08/28.

    Article  PubMed  Google Scholar 

  185. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749–54.

    Article  PubMed  CAS  Google Scholar 

  186. Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol. 2003;82(4):218–22.

    PubMed  CAS  Google Scholar 

  187. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910–6. Epub 2010/08/04.

    Article  PubMed  CAS  Google Scholar 

  188. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596–603. Epub 2012/06/30.

    Article  PubMed  PubMed Central  Google Scholar 

  189. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem. 2005;51(8):1405–10.

    Article  PubMed  CAS  Google Scholar 

  190. Nousiainen T, Vanninen E, Jantunen E, Puustinen J, Remes J, Rantala A, et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med. 2002;251(3):228–34.

    Article  PubMed  CAS  Google Scholar 

  191. Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J. 1998;136(2):362–3.

    Article  PubMed  CAS  Google Scholar 

  192. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213–20.

    Article  PubMed  CAS  Google Scholar 

  193. Sieswerda E, van Dalen EC, Postma A, Cheuk Daniel KL, Caron Huib N, Kremer Leontien CM. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst Rev. 2011;9:CD008011. Available from: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD008011/frame.html

    Google Scholar 

  194. Lipshultz SE, Lipsitz SR, Sallan SE, Simbre Ii VC, Shaikh SL, Mone SM, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002;20(23):4517–22.

    Article  PubMed  CAS  Google Scholar 

  195. Rudzinski T, Ciesielczyk M, Religa W, Bednarkiewicz Z, Krzeminska-Pakula M. Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator. Europace. 2007;9(5):278–80.

    Article  PubMed  Google Scholar 

  196. Fridericia LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand. 1920;53(1):489–506.

    Article  Google Scholar 

  197. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart. 1920;7:353–70.

    Google Scholar 

  198. Bazett HC. An analysis of the time-relations of electrocardiograms. Ann Noninvasive Electrocardiol. 1997;2(2):177–94.

    Article  Google Scholar 

  199. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol. 1992;70(7):797–801.

    Article  PubMed  CAS  Google Scholar 

  200. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia. 2002;16(4):617–22.

    Article  PubMed  CAS  Google Scholar 

  201. De Bono JS, Kristeleit R, Tolcher A, Fong P, Pacey S, Karavasilis V, et al. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res. 2008;14(20):6663–73.

    Article  PubMed  CAS  Google Scholar 

  202. Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol. 2006;1(9):1002–9.

    Article  PubMed  Google Scholar 

  203. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pešek M, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2007;25(27):4270–7.

    Article  PubMed  CAS  Google Scholar 

  204. Hazarika M, Jiang X, Liu Q, Lee SL, Ramchandani R, Garnett C, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res. 2008;14(17):5325–31.

    Article  PubMed  CAS  Google Scholar 

  205. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer. 2010;116(6):1582–91.

    Article  PubMed  CAS  Google Scholar 

  206. Camidge DR, Gail Eckhardt S, Gore L, O’Bryant CL, Leong S, Basche M, et al. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anti-Cancer Drugs. 2008;19(1):77–84. Epub 2007/11/29.

    Article  PubMed  CAS  Google Scholar 

  207. Talapatra K, Rajesh I, Rajesh B, Selvamani B, Subhashini J. Transient asymptomatic bradycardia in patients on infusional 5-fluorouracil. J Cancer Res Ther. 2007;3(3):169–71.

    Article  PubMed  CAS  Google Scholar 

  208. Altundaǧ Ö, Çelik I, Kars A. Recurrent asymptomatic bradycardia episodes after cisplatin infusion [1]. Ann Pharmacother. 2001;35(5):641–2.

    Article  PubMed  Google Scholar 

  209. Canobbio L, Fassio T, Gasparini G. Cardiac arrhythmia: possible complication from treatment with cisplatin. Tumori. 1986;72(2):201–4.

    Article  PubMed  CAS  Google Scholar 

  210. Hashimi LA, Khalyl MF, Salem PA. Supraventricular tachycardia. A probable complication of platinum treatment. Oncology. 1984;41(3):174–5.

    Article  PubMed  CAS  Google Scholar 

  211. Gridelli C, Cigolari S, Gallo C, Manzione L, Ianniello GP, Frontini L, et al. Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small-cell lung cancer elderly patients: phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer. 2001;31(2–3):277–84.

    Article  CAS  PubMed  Google Scholar 

  212. Santini D, Tonini G, Abbate A, Di Cosimo S, Gravante G, Vincenzi B, et al. Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity. Ann Oncol. 2000;11(4):479–81.

    Article  PubMed  CAS  Google Scholar 

  213. Sauer-Heilborn A, Kath R, Schneider CP, Höffken K. Severe non-haematological toxicity after treatment with gemcitabine. J Cancer Res Clin Oncol. 1999;125(11):637–40.

    Article  PubMed  CAS  Google Scholar 

  214. Zwitter M, Kovac V, Smrdel U, Kocijancic I, Segedin B, Vrankar M. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anti-Cancer Drugs. 2005;16(10):1129–34.

    Article  PubMed  CAS  Google Scholar 

  215. Lin LL, Picus J, Drebin JA, Linehan DC, Solis J, Strasberg SM, et al. A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma. Am J Clin Oncol. 2005;28(3):234–41.

    Article  PubMed  CAS  Google Scholar 

  216. Kilickap S, Akgul E, Aksoy S, Aytemir K, Barista I. Doxorubicin-induced second degree and complete atrioventricular block. Europace. 2005;7(3):227–30.

    Article  PubMed  Google Scholar 

  217. Kilickap S, Barista I, Akgul E, Aytemir K, Aksoy S, Tekuzman G. Early and late arrhythmogenic effects of doxorubicin. South Med J. 2007;100(3):262–5.

    Article  PubMed  Google Scholar 

  218. Margolin KA, Raynor AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol. 1989;7(4):486–98.

    Article  PubMed  CAS  Google Scholar 

  219. Lee RE, Lotze MT, Skibber JM, Tucker E, Bonow RO, Ognibene FP, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol. 1989;7(1):7–20.

    Article  PubMed  CAS  Google Scholar 

  220. Moreau P, Milpied N, Mahé B, Juge-Morineau N, Rapp MJ, Bataille R, et al. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant. 1999;23(10):1003–6.

    Article  PubMed  CAS  Google Scholar 

  221. Phillips GL, Meisenberg B, Reece DE, Adams VR, Badros A, Brunner J, et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant. 2004;10(7):473–83.

    Article  PubMed  CAS  Google Scholar 

  222. Mileshkin LR, Seymour JF, Wolf MM, Gates P, Januszewicz EH, Joyce P, et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma. 2005;46(11):1575–9.

    Article  PubMed  CAS  Google Scholar 

  223. Lonial S, Kaufman J, Tighiouart M, Nooka A, Langston AA, Heffner LT, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res. 2010;16(20):5079–86.

    Article  PubMed  CAS  Google Scholar 

  224. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367(9513):825–31.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain

    I. Brana, E. Zamora & J. Tabernero

  2. Cardiology Department, Vall d’Hebron University Hospital, Barcelona, Spain

    G. Oristrell

Authors
  1. I. Brana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Zamora
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Oristrell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Tabernero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Brana .

Editor information

Editors and Affiliations

  1. Department of Hematology-Oncology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg

    Mario A. Dicato

  2. Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium

    Eric Van Cutsem

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Brana, I., Zamora, E., Oristrell, G., Tabernero, J. (2018). Cardiotoxicity. In: Dicato, M., Van Cutsem, E. (eds) Side Effects of Medical Cancer Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-70253-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-70253-7_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-70252-0

  • Online ISBN: 978-3-319-70253-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation